Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine.
We evaluated the cost-effectiveness of rotavirus vaccination in Uzbekistan from the healthcare system and societal perspectives. Disease burden was estimated using national statistics on hospitalizations and deaths, and international estimates of under-five mortality. Without vaccination, the risk for rotavirus hospitalization by age 5 is 10 per 1000 children. Rotavirus hospitalizations cost US$ 406,000 annually, of which US$ 360,000 (89%) is for medical expenses and US$ 46,000 (11%) is for non-medical and indirect costs. Rotavirus mortality rate at 0.7 per 1000 derived from national data was three-fold lower than the same rate calculated from international estimates of under-five mortality. Rotavirus vaccination could reduce hospitalizations and deaths by 91% and avert US$ 370,000 in hospitalization costs alone. Vaccination would be cost-effective with vaccine prices in a range of US$ 2-25 per child. However, the cost-effectiveness is greatly influenced by mortality, vaccine price and vaccine efficacy.
Isakbaeva
E T
ET
Viral Gastroenteritis Section, Centers for Disease Control and Prevention, Atlanta, GA, USA. elmira.isakbaeva@fhi.no
Musabaev
E
E
Antil
L
L
Rheingans
R
R
Juraev
R
R
Glass
R I
RI
Bresee
J S
JS
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D017048:Health Care Costs; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D022243:Rotavirus Vaccines / Q000191:economics / Q000276:immunology*; D014611:Vaccination / Q000191:economics*
D022243:Rotavirus Vaccines